Free Trial

Senti Biosciences (SNTI) Competitors

Senti Biosciences logo
$1.68 -0.02 (-1.18%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$1.66 -0.01 (-0.89%)
As of 08/1/2025 07:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

SNTI vs. CGC, FDMT, YMAB, OGI, ENGN, RAPT, CTMX, CYBN, SXTC, and CRBU

Should you be buying Senti Biosciences stock or one of its competitors? The main competitors of Senti Biosciences include Canopy Growth (CGC), 4D Molecular Therapeutics (FDMT), Y-mAbs Therapeutics (YMAB), Organigram Global (OGI), enGene (ENGN), Rapt Therapeutics (RAPT), CytomX Therapeutics (CTMX), Cybin (CYBN), China SXT Pharmaceuticals (SXTC), and Caribou Biosciences (CRBU). These companies are all part of the "pharmaceutical products" industry.

Senti Biosciences vs. Its Competitors

Senti Biosciences (NASDAQ:SNTI) and Canopy Growth (NASDAQ:CGC) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, valuation, dividends, analyst recommendations, profitability, media sentiment, institutional ownership and earnings.

Senti Biosciences currently has a consensus price target of $8.50, indicating a potential upside of 405.95%. Given Senti Biosciences' stronger consensus rating and higher possible upside, research analysts clearly believe Senti Biosciences is more favorable than Canopy Growth.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Senti Biosciences
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00
Canopy Growth
2 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

25.7% of Senti Biosciences shares are owned by institutional investors. Comparatively, 3.3% of Canopy Growth shares are owned by institutional investors. 3.1% of Senti Biosciences shares are owned by insiders. Comparatively, 1.3% of Canopy Growth shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Senti Biosciences has higher earnings, but lower revenue than Canopy Growth. Canopy Growth is trading at a lower price-to-earnings ratio than Senti Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Senti BiosciencesN/AN/A-$52.79M-$10.84-0.15
Canopy Growth$225.65M0.95-$429.86M-$4.04-0.26

In the previous week, Canopy Growth had 3 more articles in the media than Senti Biosciences. MarketBeat recorded 3 mentions for Canopy Growth and 0 mentions for Senti Biosciences. Canopy Growth's average media sentiment score of 0.51 beat Senti Biosciences' score of 0.00 indicating that Canopy Growth is being referred to more favorably in the news media.

Company Overall Sentiment
Senti Biosciences Neutral
Canopy Growth Positive

Senti Biosciences has a beta of 2.09, meaning that its share price is 109% more volatile than the S&P 500. Comparatively, Canopy Growth has a beta of 0.68, meaning that its share price is 32% less volatile than the S&P 500.

Senti Biosciences has a net margin of 0.00% compared to Canopy Growth's net margin of -195.76%. Canopy Growth's return on equity of -88.54% beat Senti Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Senti BiosciencesN/A -177.24% -67.38%
Canopy Growth -195.76%-88.54%-40.78%

Summary

Senti Biosciences beats Canopy Growth on 9 of the 15 factors compared between the two stocks.

Get Senti Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for SNTI and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SNTI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SNTI vs. The Competition

MetricSenti BiosciencesMED IndustryMedical SectorNASDAQ Exchange
Market Cap$44.34M$3.00B$5.48B$9.51B
Dividend YieldN/A2.43%4.73%4.08%
P/E Ratio-0.1517.6228.6723.80
Price / SalesN/A179.18373.9066.65
Price / CashN/A41.9535.4557.96
Price / Book0.328.508.275.55
Net Income-$52.79M-$55.06M$3.24B$259.03M
7 Day Performance-12.95%-3.98%-3.69%-4.59%
1 Month Performance-23.98%9.59%4.33%4.46%
1 Year Performance-18.45%6.72%25.95%18.03%

Senti Biosciences Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SNTI
Senti Biosciences
1.7663 of 5 stars
$1.68
-1.2%
$8.50
+406.0%
-22.2%$44.34MN/A-0.154
CGC
Canopy Growth
0.6272 of 5 stars
$1.12
+2.8%
N/A-84.5%$200.41M$225.65M-0.283,150News Coverage
Upcoming Earnings
FDMT
4D Molecular Therapeutics
2.5461 of 5 stars
$4.24
+0.5%
$29.56
+597.1%
-62.7%$195.49M$40K-1.33120News Coverage
Upcoming Earnings
Analyst Forecast
Gap Up
YMAB
Y-mAbs Therapeutics
2.302 of 5 stars
$4.33
+0.5%
$15.60
+260.3%
-61.1%$195.17M$87.68M-6.77150News Coverage
Positive News
Short Interest ↑
OGI
Organigram Global
1.144 of 5 stars
$1.46
+0.7%
N/A-15.3%$194.21M$117.47M14.60860News Coverage
ENGN
enGene
3.4672 of 5 stars
$3.85
+1.6%
$23.29
+504.8%
-56.5%$193.69MN/A-2.3331
RAPT
Rapt Therapeutics
4.0217 of 5 stars
$11.70
+0.2%
$19.80
+69.2%
-58.0%$193.14M$1.53M-0.6180Upcoming Earnings
Analyst Upgrade
Gap Down
CTMX
CytomX Therapeutics
4.0091 of 5 stars
$2.38
-0.4%
$5.33
+124.1%
+75.4%$192.28M$147.56M4.96170News Coverage
Upcoming Earnings
Analyst Forecast
CYBN
Cybin
2.5864 of 5 stars
$8.03
-3.5%
$85.00
+958.5%
N/A$191.56MN/A-1.8350High Trading Volume
SXTC
China SXT Pharmaceuticals
0.4957 of 5 stars
$1.62
-1.3%
N/A-80.3%$191.04M$1.93M0.0090News Coverage
Analyst Upgrade
CRBU
Caribou Biosciences
2.4417 of 5 stars
$2.07
+1.0%
$8.50
+310.6%
-12.9%$190.66M$9.99M-1.28100Upcoming Earnings
Gap Down

Related Companies and Tools


This page (NASDAQ:SNTI) was last updated on 8/2/2025 by MarketBeat.com Staff
From Our Partners